• TEXT SIZE

Results with ENBREL in
Ankylosing Spondylitis (AS)

In 2003, ENBREL became the first biologic approved as a treatment option for ankylosing spondylitis (AS).

Proven results

In medical studies, ENBREL has been shown to significantly reduce the symptoms of ankylosing spondylitis. Many AS patients using ENBREL experienced a greater reduction in back pain (including nighttime pain), inflammation, and morning stiffness; improved spinal mobility; and an improvement in the ability to do everyday tasks. ENBREL was shown to be effective in about 3 out of 5 adults. Clinical responses were seen at 2 weeks in 46% of patients, with 59% of patients receiving benefit within 8 weeks.

Your results may vary. Because ENBREL works on the immune system, it can lower the ability of your immune system to fight infections and may raise other safety concerns. Please see Prescribing Information, Important Safety Information, and Medication Guide for complete details about ENBREL.

Prescription ENBREL is taken by injection.

IMPORTANT SAFETY INFORMATION
Indication

Ankylosing Spondylitis (AS)
ENBREL is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis.

Supportive data
Ankylosing Spondylitis (AS)
  • ENBREL was shown to be effective in about 3 out of 5 adults at 6 months. Clinical responses were seen at 2 weeks in 46% of patients, with 59% of patients receiving benefit within 8 weeks.
How do I know if I have AS?

Before your next appointment with your doctor, download these questions to help guide your conversation.

Diagnosed with AS?

Sign up today for more information about ankylosing spondylitis and ENBREL.

SIGN UP TODAY